Is OnKure Therapeutics, Stock a Good Investment?
OnKure Therapeutics, Investment Advice | OKUR |
- Examine OnKure Therapeutics,'s financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research OnKure Therapeutics,'s leadership team and their track record. Good management can help OnKure Therapeutics, navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceutical Products space and any emerging trends that could impact OnKure Therapeutics,'s business and its evolving consumer preferences.
- Compare OnKure Therapeutics,'s performance and market position to its competitors. Analyze how OnKure Therapeutics, is positioned in terms of product offerings, innovation, and market share.
- Check if OnKure Therapeutics, pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about OnKure Therapeutics,'s stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in OnKure Therapeutics, stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if OnKure Therapeutics, is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine OnKure Therapeutics, Stock
Researching OnKure Therapeutics,'s stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company had not issued any dividends in recent years.
To determine if OnKure Therapeutics, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding OnKure Therapeutics,'s research are outlined below:
| OnKure Therapeutics, had very high historical volatility over the last 90 days | |
| OnKure Therapeutics, has a very high chance of going through financial distress in the upcoming years | |
| OnKure Therapeutics, was previously known as Reneo Pharmaceuticals and was traded on NASDAQ Exchange under the symbol RPHM. | |
| Net Loss for the year was (35.31 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| OnKure Therapeutics, has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: OnKure Announces New Date for Upcoming Investor Call |
Basic technical analysis of OnKure Stock
As of the 28th of November, OnKure Therapeutics, holds the coefficient of variation of (5,305), and Risk Adjusted Performance of (0.01). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of OnKure Therapeutics,, as well as the relationship between them. Please check OnKure Therapeutics, variance and skewness to decide if OnKure Therapeutics, is priced some-what accurately, providing market reflects its current price of 14.76 per share. Given that OnKure Therapeutics, has information ratio of (0.05), we recommend you to check out OnKure Therapeutics,'s recent market performance to make sure the company can sustain itself at a future point.OnKure Therapeutics,'s insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific OnKure Therapeutics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on OnKure Therapeutics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases OnKure Therapeutics, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Jansen Valerie Malyvanh few days ago Acquisition by Jansen Valerie Malyvanh of 15300 shares of OnKure Therapeutics, at 18.2 subject to Rule 16b-3 | ||
Manke Isaac over a month ago Acquisition by Manke Isaac of 15300 shares of OnKure Therapeutics, at 18.2 subject to Rule 16b-3 | ||
Leonard Braden Michael over a month ago Acquisition by Leonard Braden Michael of 3457 shares of OKUR New subject to Rule 16b-3 | ||
Saccomano Nicholas A over a month ago Acquisition by Saccomano Nicholas A of 4556 shares of OnKure Therapeutics, subject to Rule 16b-3 |
Understand OnKure Therapeutics,'s technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing OnKure Therapeutics,'s various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | 0.2688 | |||
| Mean Deviation | 2.7 | |||
| Coefficient Of Variation | (5,305) | |||
| Standard Deviation | 3.63 | |||
| Variance | 13.14 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.04) | |||
| Total Risk Alpha | (0.65) | |||
| Treynor Ratio | 0.2588 | |||
| Maximum Drawdown | 15.91 | |||
| Value At Risk | (6.69) | |||
| Potential Upside | 5.88 | |||
| Skewness | 0.0721 | |||
| Kurtosis | 0.1713 |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | 0.2688 | |||
| Mean Deviation | 2.7 | |||
| Coefficient Of Variation | (5,305) | |||
| Standard Deviation | 3.63 | |||
| Variance | 13.14 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.04) | |||
| Total Risk Alpha | (0.65) | |||
| Treynor Ratio | 0.2588 | |||
| Maximum Drawdown | 15.91 | |||
| Value At Risk | (6.69) | |||
| Potential Upside | 5.88 | |||
| Skewness | 0.0721 | |||
| Kurtosis | 0.1713 |
Consider OnKure Therapeutics,'s intraday indicators
OnKure Therapeutics, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of OnKure Therapeutics, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 7093.09 | |||
| Daily Balance Of Power | (0.22) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 15.03 | |||
| Day Typical Price | 14.94 | |||
| Price Action Indicator | (0.40) | |||
| Period Momentum Indicator | (0.26) | |||
| Relative Strength Index | 46.57 |
OnKure Stock media impact
Far too much social signal, news, headlines, and media speculation about OnKure Therapeutics, that are available to investors today. That information is available publicly through OnKure media outlets and privately through word of mouth or via OnKure internal channels. However, regardless of the origin, that massive amount of OnKure data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of OnKure Therapeutics, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of OnKure Therapeutics, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to OnKure Therapeutics,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive OnKure Therapeutics, alpha.
OnKure Therapeutics, Corporate Management
| Kevin Litwiler | Senior Pharmacology | Profile | |
| Jason CPA | Chief Officer | Profile | |
| Pr Liu | Member Board | Profile | |
| Rogan JD | General Secretary | Profile | |
| Dylan Hartley | Chief Officer | Profile | |
| Richard Woessner | Senior Pharmacology | Profile |
Additional Tools for OnKure Stock Analysis
When running OnKure Therapeutics,'s price analysis, check to measure OnKure Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OnKure Therapeutics, is operating at the current time. Most of OnKure Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of OnKure Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OnKure Therapeutics,'s price. Additionally, you may evaluate how the addition of OnKure Therapeutics, to your portfolios can decrease your overall portfolio volatility.